MENU
CLVT
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

Clarivate (CLVT) Earnings Date & Reports

Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare... Show more

A.I. Advisor
published Earnings

CLVT is expected to report earnings to fall 2.30% to 19 cents per share on March 02

Clarivate CLVT Stock Earnings Reports
Q4'26
Est.
$0.20
Q3'26
Beat
by $0.04
Q2'26
Beat
by $0.01
Q1'26
Beat
by $0.04
Q4'25
Beat
by $0.04
The last earnings report on November 03 showed earnings per share of 20 cents, beating the estimate of 15 cents. With 5.70M shares outstanding, the current market capitalization sits at 1.50B.
A.I.Advisor
Nov 03, 2026

Clarivate (CLVT) Third Quarter 2026 Earnings Recap: A Leaner Business Chases a Growth Inflection

Key Takeaways

  • Clarivate Plc reported third quarter 2026 revenue from continuing operations of $481.6 million, down 9.2% from $530.3 million a year earlier, primarily due to divestitures and product wind-downs.
  • Adjusted diluted earnings per share (EPS) rose to $0.21, up from $0.18 in the prior-year period and ahead of consensus estimates of roughly $0.18.
  • Organic revenue growth turned modestly positive at 0.4%, while organic annualized contract value (ACV) growth reached 1.8%, led by a return to growth in the Intellectual Property (IP) segment.
  • Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) for continuing operations was $218.2 million, with the margin expanding to 45.3% on cost efficiencies.
  • The company completed the sale of its Life Sciences & Healthcare (LS&H) segment on October 6, 2026 for $488.4 million in net proceeds, sharpening its focus on Academia & Government and IP.
  • For deeper coverage of this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
  • Discover automated trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Clarivate's third quarter 2026 results mark a pivotal moment in the company's multi-year transformation. The early completion of the Life Sciences & Healthcare divestiture leaves a more focused, recurring-revenue-driven business centered on two scaled franchises, Academia & Government and Intellectual Property, with roughly 93% of revenue now recurring. Investors have been watching closely for evidence that the company's cost discipline and artificial intelligence (AI) initiatives can translate into durable organic growth. The report also matters because it resets full-year guidance to reflect the divested segment, giving the market a cleaner view of the go-forward earnings power and cash generation of the remaining operations.

Reported Results

Clarivate reported third quarter revenue from continuing operations of $481.6 million, down 9.2% from $530.3 million in the prior-year quarter. The decline was driven primarily by inorganic disposals, including the wind-down of the Academia & Government books business. Organic revenue growth was 0.4%, reflecting 1.5% organic subscription growth and 0.7% organic re-occurring growth, partially offset by lower transactional revenue.

Adjusted diluted EPS was $0.21, an increase of $0.03 versus the prior year and ahead of the consensus estimate of about $0.18. Adjusted EBITDA from continuing operations was $218.2 million, with the adjusted EBITDA margin widening to 45.3% from 41.9% a year earlier. On a GAAP (Generally Accepted Accounting Principles) basis, the company reported a net loss of $80.8 million, or $0.13 per diluted share, compared with a net loss of $28.3 million in the prior year, largely due to a $62.2 million non-cash goodwill impairment tied to the LS&H segment.

Organic ACV growth was 1.8%, a 30-basis-point improvement year over year. Free cash flow was $110.2 million for the quarter, while total debt declined by $293.8 million year to date.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like Clarivate through periods of restructuring and recovery, the AI Screener can surface relevant opportunities quickly and systematically.

Market Reaction and Investor Sentiment

Heading into the report, sentiment around Clarivate remained cautious, with the stock trading well below its 200-day moving average after giving back much of its mid-year rally. Investors were focused on whether the company could deliver the recurring-growth inflection management had been signaling, while also bracing for lower full-year guidance following the divestiture. The initial market reaction was positive, with shares moving higher as the market rewarded the EPS beat, margin expansion, and the return to positive ACV growth in the IP segment. Still, the revenue shortfall and trimmed full-year organic growth and free cash flow targets tempered enthusiasm, underscoring that the recovery remains modest and heavily back-end loaded to the fourth quarter.

Forward Outlook and Key Factors to Monitor

Following the divestiture, Clarivate updated its full-year 2026 outlook to reflect continuing operations only. Management now expects revenue of $1.965 billion to $1.985 billion, adjusted EBITDA of $865 million to $885 million, adjusted diluted EPS of $0.73 to $0.77, and free cash flow of $320 million to $340 million. The company also guided to organic ACV growth of 1.75% to 2.25%.

The most important near-term test is the fourth quarter, where management expects recurring organic revenue growth to exceed 2%, which would mark the highest quarterly level in more than three years. Investors should watch whether ACV gains broaden beyond pricing into genuine volume growth, and whether transactional revenue headwinds continue to fade as low-margin products are wound down.

Beyond the quarter, key catalysts include the November early-adopter launch of IPOne, the company's AI-native intelligence layer, and continued customer adoption of Web of Science Research Intelligence. Management also offered an early 2027 view of higher organic ACV and recurring revenue growth, free cash flow growth of 10% to 15%, and further debt reduction. Balance sheet progress, the pace of leverage reduction, and foreign exchange impacts on profitability remain important factors to monitor through the remainder of the year.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of activated carbon and related products and systems

Industry InformationTechnologyServices

Industry
Financial Conglomerates
Address
70 Street Mary Axe
Phone
+44 2074334000
Employees
12000
Web
https://www.clarivate.com